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prototype of the DA provides clear information about the 
treatment options and their side-effects. Issues about the 
usability of the DA were reported and enabled us to improve 
and simplify the DA. The next step is to perform a study to 
establish the impact of the DA on the decisional conflict and 
the shared decision making process.  
 
Conclusion: The systematic and iterative approach used to 
develop and validate the DA, allows to follow a thoroughly 
development process, and to gain knowledge about decisional 
needs.  
 
Poster Viewing: 11: Clinical: Breast, head and neck  
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Purpose or Objective: Van Werkhoven et al. developed a 
nomogram to predict the 10-years ipsilateral breast relapse 
(IBR) after breast conserving therapy (BCT) for breast cancer 
(BC) based on the European Organisation for Research and 
Treatment of Cancer (EORTC) ‘boost no boost’-trial with a 
concordance probability estimate (CPE) of 0.68 (van 
Werkhoven E, et al. 2011, Radiother Oncol). The nomogram 
includes histologic grade, ductal carcinoma in situ (DCIS), 
tumour diameter, age, tamoxifen, chemotherapy and boost. 
The aim of this study was to evaluate the performance of 
that algorithm in an independent cohort. 
 
Material and Methods: We retrospectively identified 1866 BC 
patients who underwent BCT with radiotherapy from 2000 to 
2007.  
Two definitions of IBR were considered where simultaneous 
regional or distant recurrence were either censored (conform 
EORTC analysis) or included as event.  
Patient, tumour and treatment characteristics were 
evaluated in uni- and multivariable analysis.  
Firstly we assessed discrimination, i.e. the extent to which 
patients predicted to be at higher risk exhibit higher event 
rates than those deemed at lower risk, by the CPE. The CPE 
was determined based on a Cox model with time to IBR as 
outcome and the EORTC nomogram 10-years IBR-free 
probability as the only covariate. Secondly a calibration plot 
was drawn, showing the predicted 10-years IBR-free 
probabilities against observed Kaplan–Meier estimates, to 
reflect prediction accuracy, i.e. the absence of over- or 
underestimation. 
 
Results: Median follow-up time was 10.75 years.  
Patients were on average older (58 vs 54 years), had a larger 
average tumour diameter (18 mm vs 15 mm) and were more 
likely to have received chemotherapy (29.7 % vs 15.7 %), to 
have a high grade disease (37.0 % vs 23.5 %) and to have a 
DCIS (69.8 % vs 57.8 %). Twenty-three percent of the patients 
received tamoxifen in the EORTC group, whereas 81.6 % 
received hormonal therapy in the validation group. Almost all 
patients (99.7 %) in the validation group received a boost 
versus 50.4 % in the EORTC cohort. Noteworthy on the 
variables not included in the nomogram, patients in the 
validation cohort had a higher percentage of oestrogen and 
progesterone receptor positivity (86.4 % vs 71.7 % and 75.9 % 
vs 64.3 %, respectively) and 10.2 % had HER2 overexpression. 
The 10-years IBR-rate was 1.4 %. On multivariable analysis, 
only the omission of the boost dose was a significant 
prognosticator of IBR (p < 0.01) with a trend for age (p = 
0.06).  
The nomogram demonstrated suboptimal discrimination, with 
a CPE of 0.54, and suboptimal calibration with an 
overestimation of the IBR-risk in general (Table 1 – Figure 1). 
 
 
 
 
Conclusion: The EORTC predictive model for IBR in BC 
patients lacks accuracy in this more recent study population. 
Therefore the model should be tested and verified in 
additional, large patient populations and incorporating 
molecular subtyping might be needed. 
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Purpose or Objective: To evaluate acute toxicity and early 
clinical outcomes of hypofractionated simultaneous 
integrated boost (SIB) approach with Volumetric Modulated 
Arc Therapy (VMAT) as adjuvant treatment after breast-
conserving surgery. 
 
Material and Methods: Patients presenting early-stage breast 
cancer were enrolled in a phase II trial. Eligibility criteria 
were as follow: age >18  years, invasive cancer or DCIS, Stage 
I to II (T <3 cm and N ≤ 3), breast -conserving surgery, any 
systemic therapy was allowed in neoadjuvant or adjuvant 
setting. All patients underwent VMAT-SIB technique to 
irradiate the whole breast with concomitant boost irradiation 
of the tumor bed. Doses to whole breast and surgical bed 
were 40.5 Gy and 48 Gy respectively, delivered in 15 
fractions over 3 weeks Acute skin toxicities were recorded 
according to RTOG scoring criteria, and late skin toxicities 
according to CTCAE v4.0. Cosmetic outcomes were assessed 
as excellent/good or fair/poor according to the Harvard 
scale. 
 
Results: Between August 2010 and January 2015, 840 
consecutive patients were treated. Median age was 60 year 
(range 19-89 years). The median follow up was 16 months 
(range 6-55). At the end of RT treatment skin toxicity profile 
was G1 in 49% of the patients, G2 in 13%, and one patients 
presented G3 toxicity (0.1%). At six months of follow up skin 
toxicity was G1 in 27% of patients, G2 in 1%, no G3 cases; 
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cosmetic outcome was good/excellent in 94% of patients. At 
one year skin toxicity was G1 in 13% of patients, 1 patient 
G2, 1 patient G3; cosmetic outcome was good/excellent in 
93% of patients.After an early evaluation of clinical outcomes 
we have found 12 cases of progression disease, only one 
patient had an In-Breast-Recurrence. 
 
Conclusion: The 3-week course of postoperative radiation 
using VMAT with SIB was well tolerated in acute and early 
late settings. Long-term follow-up data are needed to assess 
late toxicity and clinical outcomes. 
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Purpose or Objective: Breast cancer (BC) could be classified 
into four major molecular subtypes: Luminal-A, Luminal-B, 
triple negative/basal-like, human epidermal growth factor 2 
(HER2) enriched. This classification could be based on 
immunohistochemistry, and may allow the clinicians to 
optimize treatment management. Luminal-A tumors 
represent around 40% of BC and are characterized by: 
estrogen receptor (ER) and/or progesterone receptor (PgR) 
positive, HER2/neu negative, and low Ki-67 proliferative 
index. Early luminal-A tumors tend to have an excellent 
prognosis, with high survival and low recurrence rates. The 
aim of this analysis was to observe Luminal-A outcome from a 
phase 3 trial comparing whole-breast irradiation (WBI) to 
accelerated partial breast irradiation (APBI) using intensity-
modulated radiotherapy (IMRT) technique. 
 
Material and Methods: In the whole trial 520 patients were 
randomized in 1:1 ratio to receive APBI versus WBI after 
breast conserving surgery for early BC. The primary endpoint 
was occurrence of ipsilateral breast tumor recurrence (IBTR); 
the main analysis was by intention-to-treat. This trial was 
registered with ClinicalTrials.gov, number NCT02104895. 
 
Results: Luminal-A patients represented the 61.5% of the 
whole series (151 WBI versus 169 APBI). 5-year event rate 
according to allocated group showed no statistical difference 
in terms of IBTR (p=0.53). One case (0.9%) versus two cases 
(1.7%) were observed in the WBI and APBI arms, respectively. 
Survival events occurrences and IBTR curve are summarized 
in the Figures. 
 
 
 
 
Conclusion: We observed a very low 5-year rate of IBTR for 
Luminal-A patients treated with APBI. Although these results 
should be confirmed at a longer follow up time, this approach 
should be considered for this subset of early BC patients. 
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Purpose or Objective: To evaluate toxicity in breast cancer 
patients treated with anthracycline and taxane based 
chemotherapy and whole breast hypofractionated 
radiotherapy, and to identify the risk factors for toxicity. 
 
Material and Methods: From April 2009 to December 2014, 
540 patients received radiotherapy after breast conservative 
surgery (BCS). The dose was 42.4 Gy in 16 daily fractions, 
2.65 Gy per fraction. The boost to the tumor bed was 
administered only in grade 3 patients and in patients with 
close or positive margins. Acute and late toxicity were 
prospectively assessed during and after radiotherapy 
according to RTOG scale. The impact of patients clinical 
characteristics and dose inhomogeneities on the occurrence 
of an higher level of toxicity has been also evaluated by 
univariate and multivariate analysis. 
 
Results: One hundred and nineteen patients received 
chemotherapy. Sixty-one patients (11.3%) underwent 
trastuzumab therapy and four hundred and forty-one (81.6%) 
hormonotherapy. The mean age was 74 (range 46-91 yrs). 
Forty seven (8.7%) and two hundred fifty eight (47.5%) 
patients were affected by diabetes mellitus and 
hypertension, respectively. G1 and G2/G3 acute skin toxicity 
were 53.7% and 28.5% in patients received chemotherapy and 
63.2% and 18.5% in patients who did not receive it, 
respectively. No significant difference (p=0.092) was find 
